These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30346623)

  • 1. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.
    John F; Bosnyák E; Robinette NL; Amit-Yousif AJ; Barger GR; Shah KD; Michelhaugh SK; Klinger NV; Mittal S; Juhász C
    Neuro Oncol; 2019 Feb; 21(2):264-273. PubMed ID: 30346623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI.
    Bosnyák E; Kamson DO; Robinette NL; Barger GR; Mittal S; Juhász C
    J Neurooncol; 2016 Jan; 126(2):317-25. PubMed ID: 26514361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal Imaging of Nonenhancing Glioblastoma Regions.
    John F; Robinette NL; Amit-Yousif AJ; Bosnyák E; Barger GR; Shah KD; Mittal S; Juhász C
    Mol Imaging; 2019; 18():1536012119885222. PubMed ID: 31736437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
    Bosnyák E; Michelhaugh SK; Klinger NV; Kamson DO; Barger GR; Mittal S; Juhász C
    Clin Nucl Med; 2017 May; 42(5):341-347. PubMed ID: 28195901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of glioblastomas from metastatic brain tumors by tryptophan uptake and kinetic analysis: a positron emission tomographic study with magnetic resonance imaging comparison.
    Kamson DO; Mittal S; Buth A; Muzik O; Kupsky WJ; Robinette NL; Barger GR; Juhász C
    Mol Imaging; 2013; 12(5):327-37. PubMed ID: 23759373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates.
    Kamson DO; Juhász C; Buth A; Kupsky WJ; Barger GR; Chakraborty PK; Muzik O; Mittal S
    J Neurooncol; 2013 Mar; 112(1):121-32. PubMed ID: 23299463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.
    Popp I; Bott S; Mix M; Oehlke O; Schimek-Jasch T; Nieder C; Nestle U; Bock M; Yuh WTC; Meyer PT; Weber WA; Urbach H; Mader I; Grosu AL
    Radiother Oncol; 2019 Jan; 130():121-131. PubMed ID: 30219612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.
    Kamson DO; Mittal S; Robinette NL; Muzik O; Kupsky WJ; Barger GR; Juhász C
    Neuro Oncol; 2014 Oct; 16(10):1373-83. PubMed ID: 24670609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of Multimodal MRI-Based Deep Learning Prediction of High Amino Acid Uptake Regions and Survival in Patients With Glioblastoma.
    Jeong JW; Lee MH; John F; Robinette NL; Amit-Yousif AJ; Barger GR; Mittal S; Juhász C
    Front Neurol; 2019; 10():1305. PubMed ID: 31920928
    [No Abstract]   [Full Text] [Related]  

  • 10. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Added Prognostic Value of Metabolic Tumor Size on FDG-PET at First Suspected Recurrence of Glioblastoma Multiforme.
    Chiang GC; Galla N; Ferraro R; Kovanlikaya I
    J Neuroimaging; 2017 Mar; 27(2):243-247. PubMed ID: 27515717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
    AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
    Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
    Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging.
    Holodny AI; Makeyev S; Beattie BJ; Riad S; Blasberg RG
    AJNR Am J Neuroradiol; 2010 Jun; 31(6):1042-8. PubMed ID: 20150307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.
    Deike K; Wiestler B; Graf M; Reimer C; Floca RO; Bäumer P; Kickingereder P; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    J Neurooncol; 2016 Feb; 126(3):463-72. PubMed ID: 26518541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
    Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
    AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.
    Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS
    J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.